Navigation Links
Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
Date:6/30/2011

TOKYO, June 30, 2011 /PRNewswire/ --

  • GLOW2 Study Shows NVA237 Provides Superior24-hour Bronchodilation to Placebo (p<0.001) with Comparable Efficacy to Open-Label Tiotropium at 12 Weeks
  • NVA237 Shown to be Well-Tolerated in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
  • Phase III data Support First Regulatory Submission by Novartis for NVA237 by end of 2011


 

Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), announces that results reported today by Novartis from the pivotal Phase III GLOW2 clinical trial show that once-daily NVA237 (glycopyrronium bromide) 50 mcg significantly improved lung function in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) relative to placebo (p<0.001), with similar efficacy to open-label tiotropium.

Further efficacy and safety results from GLOW2 will be presented at a scientific congress in 2012, and the data will be used to support an application for regulatory approval to be filed before the end of 2011.

Mr Shinichi Tamura, CEO of Sosei, said: "GLOW2 is the second NVA237 Phase III study to meet its primary end point and further endorses the benefit of NVA237 in COPD patients.  We look forward to Novartis filing the product in 2011, followed by the filing of QVA149, the fixed-dose combination of NVA237 and indacaterol, expected to occur in 2012 ."

In an exploratory arm of the study, NVA237 was compared with open-label tiotropium (Spiriva® HandiHaler[® Spiriva® and HandiHaler® are registered trademarks of Boehringer Ingelheim Pharma GmbH & Co. KG.]) 18 mcg, another once-daily long-acting muscarinic antagonist (LAMA) indicated for the treatment of COPD. Results show that NVA237 produced similar improvements in lung function to tiotropium.

The study met its
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. DNA Medicine Institute Awarded Two Phase III SBIR NASA Contracts for Its rHEALTH Sensor
2. Phase I of the Swedish/Issaquah Medical Center Campus to Open in July
3. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
4. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
5. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
6. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
7. Glycotex, Inc. Releases Final Phase II Clinical Trials Results in the Clinicaltrials.gov Database and Announces the Results of the Mechanism of Action Study for its Product Candidate GLYC-101
8. Ampio Pharmaceuticals, Inc. Releases Results From Phase III Clinical Trial of Zertane™ for the Treatment of Premature Ejaculation (PE), the Most Prevalent Form of Male Sexual Dysfunction
9. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
10. Once-Monthly Exenatide Improved Glucose Control in Patients with Type 2 Diabetes: Phase 2 Study Results Presented at ADA 2011
11. New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014 Yesterday, former ... (Moberg) medical device manufacturing facility. Rep. Kennedy and ... neurological monitors facilitate cutting-edge research in neurological disease ... and mental health advocate, Garen Staglin , ... to fostering fundamental changes that will radically accelerate ...
(Date:7/10/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... the sale to Galderma of all rights to Restylane, ... Valeant for $1.4 billion in cash, pursuant to the ... its acquisition of Galderma. "We are ... a company that is firmly committed to the aesthetic ...
(Date:7/10/2014)... , July 10, 2014  Decision Resources Group ... infectious disease (ID) specialists are willing to prescribe ... (oritavancin) for use as OPAT, approximately two-thirds of ... agents to their hospital inpatients. However, our findings ... patients are initiated on OPAT following hospital discharge, ...
Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... Chronic Hepatitis B e-Antigen,(HBeAg)-Negative Patients Achieved Undetectable ... N.J., April 13, 2007 /PRNewswire-FirstCall/ --,Bristol-Myers Squibb ... of,nucleoside-naive HBeAg-negative chronic hepatitis B patients,(ETV-027/901, n=99). ... levels of hepatitis B virus in the ...
... found to dramatically reduce the risk of ... tumors,(GIST), EAST HANOVER, N.J., April 12, 2007 ... mesylate)* tablets to,patients receiving placebo in a ... analysis showed participants with Kit-positive,gastrointestinal stromal tumors ...
Cached Medicine Technology:Baraclude (entecavir) Therapy Resulted in Undetectable Levels of,Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment 2Baraclude (entecavir) Therapy Resulted in Undetectable Levels of,Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment 3Baraclude (entecavir) Therapy Resulted in Undetectable Levels of,Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment 4Baraclude (entecavir) Therapy Resulted in Undetectable Levels of,Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment 5Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study 2Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study 3Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study 4Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study 5Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study 6Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study 7
(Date:7/13/2014)... July 13, 2014 If Dr. Lawrence Power ... has just launched at http://www.HealthYourself101.com will expand people’s ... , Power has set out to provide a health ... that’s actually – dare we say it? – entertaining to ... Power, “aims to engage the remote learner – the solitary ...
(Date:7/13/2014)... 13, 2014 According to the Living ... is a comprehensive guide that features a series of ... KP (keratosis pilaris). This guide consists of 14 ... Keratosis Pilaris? ,     Chapter 2: What Cause KP? ... I Have KP? ,     Chapter 4: Keratosis Pilaris ...
(Date:7/12/2014)... 2014 According to the new market ... Airborne Systems, and Naval Systems) - Global Forecasts and ... and Surveillance Radar market are estimated to be $6.08 ... CAGR of 5.97% to reach $8.61 billion by 2020. ... 47 figures spread through 161 pages and in-depth TOC ...
(Date:7/12/2014)... July 13, 2014 Recently, iFitDress.com, one of ... selection of red evening gowns . What’s more, all ... 56% off. , The company’s senior spokesman states, “We are ... on our website is an enjoyable shopping experience. In addition ... our online store, low prices do not always mean bad ...
(Date:7/12/2014)... July 12, 2014 The Passenger Information ... in 2013 to $20,341.36 million by 2019, at an ... and 2019. , The public transport infrastructure in North ... also available in almost every corner of the region. ... interest of public transport service providers are driving the ...
Breaking Medicine News(10 mins):Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 3Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 4Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 3Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Discounted Red Evening Gown Announced by iFitDress.com 2Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 4
... suggests threat of starvation triggers the switch , , THURSDAY, ... the body,s biological clock, which regulates sleep cycles based ... be overridden in extreme situations by an internal "food ... mice and has not yet been tested among humans. ...
... DC (Thursday, May 22, 2008) For patients undergoing ... lead to an increased risk of diabetes, reports a ... of Nephrology (JASN). , "We demonstrated a robust association ... group of kidney transplant recipients in the United States," ...
... Inc. (Amex:,ADL), ( http://www.amdl.com ), a world ... and Jilin, China, announced today that,it has made ... Q1,2008 financial results conference call. The document can ... . Click on "Investor Relations",then "Recent News.", ...
... 22 The topic of today,s,congressional subcommittee hearing ... importance to Kansas and should serve several,purposes:, ... research,capability to combat the real and present threat ... and agriculture economy., * Demonstrate the urgency ...
... ... difficulties, MINNEAPOLIS, May 22 ... bringing visibility to,dysphagia -- an often undiagnosed, secondary condition resulting from ... makes swallowing extremely difficult and can lead to dangerous,health threats if ...
... involved with learning and memory , , THURSDAY, May 22 (HealthDay ... come with obstructive sleep apnea (OSA), a new study suggests. ... increased oxidative stress that affects brain tissue in areas involved ... study, published in the second issue for May of ...
Cached Medicine News:Health News:'Food Clock' May Override Master Sleep Clock in Times of Duress 2Health News:'Food Clock' May Override Master Sleep Clock in Times of Duress 3Health News:'Food Clock' May Override Master Sleep Clock in Times of Duress 4Health News:Anti-rejection drug may increase risk of diabetes after kidney transplant 2Health News:AMDL Teleconference Available on amdl.com at 5:00 p.m. EDT Today 2Health News:Tip Sheet: Kansas Responds to Congressional Hearing on Animal Disease Research 2Health News:Stroke Victims Often Suffer From Lack of Nutrients With Undiagnosed Disorder 2Health News:Stroke Victims Often Suffer From Lack of Nutrients With Undiagnosed Disorder 3Health News:Green Tea May Help Brain Cope With Sleep Disorders 2
... / Ker Accuref K 9001 ... LCD color monitor. 3 step ... 2.3 mm Minimum pupil diameter ... adjuster. Auto start function. Kerato-Peripheral ...
... Suresight is the child-friendly, portable ... children and adults. It can perform ... inches (35 cm) away even through ... flashing lights and sounds engage the ...
Neomycin and Polymyxin B sulfates and Dexamethasone ophthalmic ointment is a multiple dose anti-infective steroid combination in sterile ointment form for topical applications....
Optoelectronic stimulator, "ganzfeld" stimulations for flash VEP, flash ERG and sensory EOG. Pattern stimulations for ERG and VEP, multifocal stimulations for ERG and VEP, complies with international...
Medicine Products: